Glaukos (GKOS) to Release Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) is set to announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.59) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The business had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. During the same quarter last year, the company posted ($0.53) EPS. The firm’s revenue was up 15.7% on a year-over-year basis. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $97.26 on Tuesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. The stock’s fifty day moving average price is $92.52 and its two-hundred day moving average price is $82.10. Glaukos has a one year low of $45.38 and a one year high of $103.66. The firm has a market cap of $4.88 billion, a price-to-earnings ratio of -34.99 and a beta of 1.08.

Wall Street Analysts Forecast Growth

GKOS has been the topic of a number of research reports. Truist Financial reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Glaukos in a report on Monday, April 8th. Needham & Company LLC upped their price objective on Glaukos from $105.00 to $108.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Wells Fargo & Company upped their price objective on Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. StockNews.com lowered Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $110.00 target price on shares of Glaukos in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.80.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 59,801 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $10,232,367.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Alex R. Thurman sold 474 shares of Glaukos stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total transaction of $42,835.38. Following the transaction, the chief financial officer now owns 54,916 shares in the company, valued at $4,962,758.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 59,801 shares of Glaukos stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the transaction, the chief operating officer now directly owns 101,845 shares in the company, valued at $10,232,367.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 232,881 shares of company stock valued at $21,965,491. 6.40% of the stock is owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.